Related references
Note: Only part of the references are listed.Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs
Andrew V. Stachulski et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile
Twisha S. Patel et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2017)
Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers
Jeremy J. Lim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome
Tatiana Baranovich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice
Donald F. Smee et al.
ANTIVIRAL RESEARCH (2016)
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses
Jennifer L. McKimm-Breschkin et al.
ANTIVIRAL RESEARCH (2016)
Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir
Emi Takashita et al.
ANTIVIRAL RESEARCH (2016)
JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses
Yu Fu et al.
ANTIVIRAL RESEARCH (2016)
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015
Aeron C. Hurt et al.
ANTIVIRAL RESEARCH (2016)
Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes
Nicole L. Kallewaard et al.
CELL (2016)
Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data
Carl J. Heneghan et al.
HEALTH TECHNOLOGY ASSESSMENT (2016)
Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice
Bindumadhav M. Marathe et al.
SCIENTIFIC REPORTS (2016)
Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication
Daria Trabattoni et al.
SCIENTIFIC REPORTS (2016)
Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks
Andrew M. Wollacott et al.
EBIOMEDICINE (2016)
Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults
Jonathan M. Zenilman et al.
ANTIVIRAL RESEARCH (2015)
Neuraminidase inhibitors: who, when, where?
J. S. Nguyen-Van-Tam et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps
Hang Xie et al.
SCIENTIFIC REPORTS (2015)
Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro
Giuseppe Belardo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit
Randal A. Byrn et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management
Aeron C. Hurt et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2015)
Efficacy and Safety of Treatment With an Anti-M2e Monoclonal Antibody in Experimental Human Influenza
Eleanor L. Ramos et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Favipiravir: A New Medication for the Ebola Virus Disease Pandemic
Takashi Nagata et al.
DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS (2015)
Effect of sialidase fusion protein (DAS 181) on human metapneumovirus infection of Hep-2 cells
Sutthiwan Thammawat et al.
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY (2015)
Antiviral Susceptibility of Variant Influenza A(H3N2)v Viruses Isolated in the United States from 2011 to 2013
K. Sleeman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Jean-Francois Rossignol
ANTIVIRAL RESEARCH (2014)
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Lisa Oestereich et al.
ANTIVIRAL RESEARCH (2014)
Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model
Sophie J. Smither et al.
ANTIVIRAL RESEARCH (2014)
Broadly Neutralizing Influenza Hemagglutinin Stem-Specific Antibody CR8020 Targets Residues that Are Prone to Escape due to Host Selection Pressure
Kannan Tharakaraman et al.
CELL HOST & MICROBE (2014)
A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013
E. Takashita et al.
EUROSURVEILLANCE (2014)
An Investigational Antiviral Drug, DAS181, Effectively Inhibits Replication of Zoonotic Influenza A Virus Subtype H7N9 and Protects Mice From Lethality
Henju Marjuki et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2
Michael P. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial
Jason Haffizulla et al.
LANCET INFECTIOUS DISEASES (2014)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)
T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
Tatiana Baranovich et al.
JOURNAL OF VIROLOGY (2013)
DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient
D. R. Drozd et al.
TRANSPLANT INFECTIOUS DISEASE (2013)
Favipiravir (T-705) inhibits in vitro norovirus replication
J. Rocha-Pereira et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza Infection
Ronald B. Moss et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181
Gallen B. Triana-Baltzer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Widespread use of neuraminidase inhibitors in Japan
Norio Sugaya
JOURNAL OF INFECTION AND CHEMOTHERAPY (2011)
Community Transmission of Oseltamivir-Resistant A(H1N1)pdm09 Influenza
Aeron C. Hurt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins
Davide Corti et al.
SCIENCE (2011)
A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses
Damian C. Ekiert et al.
SCIENCE (2011)
In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses
Katrina Sleeman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis
Gallen B. Triana-Baltzer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
New Class of Monoclonal Antibodies against Severe Influenza: Prophylactic and Therapeutic Efficacy in Ferrets
Robert H. E. Friesen et al.
PLOS ONE (2010)
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
Maki Kiso et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses
Andres G. Grandea et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
DAS181 Inhibits H5N1 Influenza Virus Infection of Human Lung Tissues
Renee W. Y. Chan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa
Aeron C. Hurt et al.
ANTIVIRAL RESEARCH (2009)
Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level
Jean Francois Rossignol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein
Gallen B. Triana-Baltzer et al.
PLOS ONE (2009)
Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide
Brent E. Korba et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication
Brent E. Korba et al.
ANTIVIRAL RESEARCH (2008)
Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells
Mark Throsby et al.
PLOS ONE (2008)
DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection
Jessica A. Belser et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005-2006 season of dual A and B vaccine mismatch in Canada
D. M. Skowronski et al.
VACCINE (2007)
Efficacy of orally administered T-705 on lethal avian influenza a (H5N1) virus infections in mice
Robert W. Sidwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni
Paul S. Hoffman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection
MP Malakhov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern
RA Bright et al.
LANCET (2005)
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
P Ward et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
In vitro and in vivo activities of anti-influenza virus compound T-705
Y Furuta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Ribavirin's antiviral mechanism of action: lethal mutagenesis?
S Crotty et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2002)
Share Paper
